SAB Biotherapeutics, Inc. (SABS)
NASDAQ: SABS · Real-Time Price · USD
2.980
+0.090 (3.11%)
Oct 9, 2026, 4:00 PM EDT - Market closed
SAB Biotherapeutics Analyst Ratings
Ratings History
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| Barclays | Barclays | Buy Maintains $13 | Buy | Maintains | $13 | +336.24% | Aug 7, 2026 |
| H.C. Wainwright | H.C. Wainwright | Buy Maintains $10 | Buy | Maintains | $10 | +235.57% | Aug 7, 2026 |
Unknown Analyst Guggenheim No rating | Guggenheim | Buy Reiterates $15 | Buy | Reiterates | $15 | +403.36% | Aug 7, 2026 |
| Chardan Capital | Chardan Capital | Buy Reiterates $14 → $16 | Buy | Reiterates | $14 → $16 | +436.91% | Jun 17, 2026 |
| Craig-Hallum | Craig-Hallum | Buy Maintains $6 | Buy | Maintains | $6 | +101.34% | Jun 16, 2026 |
| Citi | Citi | Buy Reiterates $11 | Buy | Reiterates | $11 | +269.13% | Jun 16, 2026 |
| Oppenheimer | Oppenheimer | Buy Reiterates $14 | Buy | Reiterates | $14 | +369.80% | Jun 15, 2026 |
| Jefferies | Jefferies | Buy Initiates $11 | Buy | Initiates | $11 | +269.13% | May 20, 2026 |